A Medical Device Daily
Aethlon Medical (San Diego) reported that it has filed a international patent application under the Patent Cooperation Treaty (PCT), entitled "Extracorporeal Removal of Microvesicular Particles."
Microvesicular particles are secreted by tumor cells and are known to depress the immune response in cancer patients. They shield tumor cells from the immune response by inducing T-cell apoptosis and blocking T-cell signaling, proliferation, cytokine production, and cytotoxicity.
The PCT is an international patent law treaty providing a unified procedure for filing applications to protect inventions in 137 member nations. A patent application filed under the PCT is called an international application or PCT application.
Aetholon said the application is associated with early-stage research for further development of the mechanisms of the Aethlon Hemopurifier as a potential method to assist in cancer treatment.
Aethlon says its primary focus is to commercialize the Hemopurifier as "the first-in-class device to treat a broad-spectrum of infectious disease conditions."
It describes the Hemopurifier as positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
On March 6 Aethlon submitted an Investigational Device Exemption to the FDA requesting permission to initiate human safety studies of the Aethlon Hemopurifier as a treatment countermeasure against select category A bioterror threats.